SCHEMBL712775

SCHEMBL712775

O=C(O)CCCCCOc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.72
HDAC1 Q13547 6/20 0.69
HDAC2 Q92769 6/20 0.69
KCNA3 P22001 1/20 0.64
FFAR1 O14842 3/20 0.60
HDAC3 O15379 3/20 0.60
HDAC4 P56524 3/20 0.60
HDAC7 Q8WUI4 3/20 0.60
HDAC10 Q969S8 3/20 0.60
HDAC11 Q96DB2 3/20 0.60
HDAC8 Q9BY41 3/20 0.60
HDAC6 Q9UBN7 3/20 0.60
HDAC9 Q9UKV0 3/20 0.60
HDAC5 Q9UQL6 3/20 0.60
ALB P02768 1/20 0.58
FFAR4 Q5NUL3 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8864468 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL557510 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL1139655 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL11790866 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL6342300 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL25228768 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL11616532 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL503552 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL1008297 1.00 PPARA (0.72) PPARAHDAC1HDAC2KCNA3FFAR1
SCHEMBL1162023 0.98 PPARA (0.74) PPARAHDAC1HDAC2KCNA3FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220370467-A1 USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE WASHINGTON UNIVERSITY 2022-11-24 US claimed
EP-4031124-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE Reneo Pharmaceuticals, Inc. (US) 2022-07-27 EP claimed
CN-114727976-A Use of PPAR-delta agonists in the treatment of renal disease 雷内奥制药公司 2022-07-08 CN claimed
US-20220117972-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY RENEO PHARMACEUTICALS, INC. 2022-04-21 US claimed
US-20220023306-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) RENEO PHARMACEUTICALS, INC. 2022-01-27 US claimed
EP-3927718-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY Reneo Pharmaceuticals, Inc. (US) 2021-12-29 EP claimed
EP-3920903-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) Reneo Pharmaceuticals, Inc. (US) 2021-12-15 EP claimed
CN-113747891-A Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) 雷内奥制药公司 2021-12-03 CN claimed
CN-113710683-A Use of PPAR-delta agonists in the treatment of mitochondrial myopathy 雷内奥制药公司 2021-11-26 CN claimed
WO-2021055725-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE RENEO PHARMACEUTICALS, INC. (US) 2021-03-25 WO claimed
WO-2020163240-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) RENEO PHARMACEUTICALS, INC. (US) 2020-08-13 WO claimed
US-11931365-B2 Use of PPAR-delta agonists in the treatment of disease RENEO PHARMACEUTICALS, INC. (US) 2024-03-19 US disclosed
US-20240016809-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE RENEO PHARMACEUTICALS, INC. 2024-01-18 US disclosed
EP-4294878-A1 COATING COMPOSITION COMPRISING A PIGMENT PASTE COMPRISING AN ORGANIC PIGMENT AND AN ARYL-MODIFIED BRANCHED REACTION PRODUCT BASF Coatings GmbH (DE) 2023-12-27 EP disclosed
WO-2023147309-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE RENEO PHARMACEUTICALS, INC. (US) 2023-08-03 WO disclosed
EP-1113033-A2 Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same CANON KABUSHIKI KAISHA (JP) 2001-07-04 EP disclosed
EP-0487343-B1 Process for preparing a lithographic plate FUJI PHOTO FILM CO LTD (JP) 1999-04-28 EP disclosed
EP-0487343-A1 Process for preparing a lithographic plate Fuji Photo Film Co., Ltd. (JP) 1992-05-27 EP disclosed
EP-0128598-B1 THERMOPLASTIC MOULDING COMPOSITION SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-05-13 EP disclosed
US-4508541-A DETERGENTS TEXACO INC. (US) 1985-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370467-A1 USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE PPARG, PPARA, PPARD PPARA 2/4885HDAC1 1595/4885HDAC2 2519/4885
US-11931365-B2 Use of PPAR-delta agonists in the treatment of disease PPARG, PPARD, PPARA PPARA 3/4885HDAC1 721/4885HDAC2 1013/4885
US-20220117972-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY PPARD, PPARA, MTPN PPARA 2/4885HDAC1 2295/4885HDAC2 2749/4885
US-20240016809-A1 USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE PPARG, PPARD, PPARA PPARA 3/4885HDAC1 721/4885HDAC2 1013/4885
US-20220023306-A1 USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) PPARD, ACOX1, CPT1A PPARA 8/4885HDAC1 1881/4885HDAC2 1743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.